PTP-MEG1 inhibitors are a class of chemical compounds that target the protein tyrosine phosphatase non-receptor type 14 (PTPN14), commonly referred to as PTP-MEG1. PTP-MEG1 is part of the protein tyrosine phosphatase (PTP) family, which plays a crucial role in cellular signaling by dephosphorylating tyrosine residues on target proteins, thus acting as a key regulator of numerous biological processes. The PTP-MEG1 enzyme is particularly involved in pathways associated with cytoskeletal organization, cell migration, and various signal transduction processes. Inhibitors of PTP-MEG1 function by blocking its phosphatase activity, thereby modulating the downstream signaling pathways that rely on PTP-MEG1's regulation of phosphorylation states. Structurally, these inhibitors are designed to bind to the active site of PTP-MEG1, either competitively or through allosteric mechanisms, which hinders its ability to catalyze the removal of phosphate groups from specific substrate proteins.
The chemical structure of PTP-MEG1 inhibitors is diverse, often featuring scaffolds that enhance their affinity and specificity for the enzyme's active site. Many inhibitors possess a core structure that mimics the phosphate moiety or employs molecular features to interact with the unique pocket architecture of PTP-MEG1. Additionally, structural optimization to improve bioavailability, potency, and selectivity has led to a variety of derivatives that can modulate the enzyme's activity with high precision. The binding interactions between PTP-MEG1 inhibitors and the phosphatase domain are a key focus for researchers, aiming to elucidate the conformational changes induced upon binding and to understand how these changes affect the phosphatase's overall function. By studying PTP-MEG1 inhibitors, researchers gain insights into the regulatory mechanisms of phosphatases and the broader implications of tyrosine phosphorylation in cellular processes, providing valuable information on cellular signal modulation and protein interaction dynamics.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could potentially downregulate PTP-MEG1 expression by hypomethylating the gene's promoter, thereby reducing its transcriptional activity in the cell. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
By inhibiting histone deacetylases, Trichostatin A may promote acetylation of histones near the PTP-MEG1 gene, which could lead to a decrease in the gene's expression by altering chromatin structure. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid might downregulate PTP-MEG1 by binding to retinoic acid receptors that interact with the gene's promoter, thereby decreasing its transcriptional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin could inhibit the expression of PTP-MEG1 by hindering the mTOR pathway, which is often involved in the translation control of many genes, including those related to cell differentiation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
This PI3K inhibitor may lead to a decrease in PTP-MEG1 expression by attenuating the PI3K/AKT pathway, which is crucial for the translation of many growth-related proteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 could decrease PTP-MEG1 expression by blocking p38 MAPK activity, which may be necessary for the transcription of genes involved in cell cycle regulation and stress response. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibition of JNK by SP600125 may result in reduced transcriptional activity of stress response genes, potentially including PTP-MEG1, thereby lowering its expression levels. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib could downregulate PTP-MEG1 by inhibiting EGFR tyrosine kinase activity, which may disrupt downstream signaling pathways essential for the gene's expression. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib might lower PTP-MEG1 expression by targeting BCR-ABL tyrosine kinase, which is involved in a signaling cascade that can control the expression of various genes. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid may reduce PTP-MEG1 expression by hyperacetylating histones, thereby altering the chromatin conformation and decreasing the accessibility of the gene to transcriptional machinery. | ||||||